Penumbra Inc stock (US70975L1070): shares steady after recent pullback as valuation comes into focus

Penumbra Inc shares on the NYSE traded around the low 320 USD range after a recent pullback, leaving the United States-based medical device maker valued at roughly USD 13 billion and putting its valuation metrics back in focus for investors.

Penumbra Inc shares on the New York Stock Exchange were last seen around USD 319 on 05/28/2026 after regular trading, following a modest decline in the prior session that left the United States-based medical device group with a market capitalization of close to USD 13 billion, according to Nasdaq and CompaniesMarketCap data as of late May 2026.

The stock, which trades under the ticker PEN in New York, closed at about USD 319.23 on 05/28/2026, while its market value was reported at roughly USD 12.9 billion on 05/25/2026, highlighting how even small price moves shift the valuation of this mid-cap U.S. healthcare name.

The company is headquartered in Alameda, California, and is part of the U.S. medical technology universe, with its primary listing on the NYSE and financial reporting in U.S. dollars, making it a relevant name for U.S.-based health care and growth-focused portfolios.

The stock has attracted attention from investors after a strong run over the past year, and recent consolidation in the low 300 USD range now places the focus on Penumbra's valuation multiples, profitability profile, and expectations for its neurovascular and thrombectomy product pipeline.

In Germany, Penumbra shares are also available for trading via platforms such as Tradegate under the ticker PEN in euros, giving investors in the German-speaking markets an additional way to access the U.S.-listed stock alongside the primary New York listing.

Trading volumes in late May 2026 remained moderate, and the recent price action does not reflect any major fresh corporate announcement from the company itself, but rather broader sentiment toward medical technology and growth stocks as U.S. investors reassess valuations following sector-wide volatility.

For context, Penumbra continues to be followed by Wall Street analysts who monitor its revenue trajectory and margins as it rolls out new products, meaning that valuation ratios such as price-to-earnings and enterprise-value-to-EBITDA are frequently referenced when assessing the stock.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Penumbra Inc
• Sector/industry: Medical devices / healthcare technology
• Headquarters/country: Alameda, United States
• Core markets: North America, Europe, selected Asia-Pacific regions
• Key revenue drivers: Neurovascular devices, thrombectomy systems, peripheral vascular interventions
• Home exchange/listing venue: NYSE (PEN)
• Trading currency: USD

Penumbra Inc: core business model

Penumbra focuses on designing and selling minimally invasive medical devices for treating neurovascular and vascular conditions, with revenue centered on adoption of its stroke and thrombectomy product platforms in hospitals worldwide.

Valuation metrics and multiples for Penumbra Inc

With a market capitalization around USD 12.9 billion at the end of May 2026 and a share price in the low 320 USD region, Penumbra's valuation reflects expectations for continued double-digit growth in its neurovascular and mechanical thrombectomy franchises, even though the company still invests heavily in research and commercial expansion.

Based on recent market data, the stock trades at a premium to many diversified healthcare names on metrics such as price-to-sales and enterprise-value-to-revenue, a pattern that is typical for high-growth medical technology names, and investors will be watching how revenue growth, operating leverage, and regulatory milestones evolve over the coming quarters to see whether these valuation levels remain supported.

Conclusion

Penumbra Inc shares on the NYSE are trading near USD 319 after a modest recent pullback, leaving the California-based medical device group valued at close to USD 13 billion and drawing attention back to how the market prices its growth profile.

On current market data, valuation ratios such as price-to-sales and enterprise-value-to-revenue remain elevated compared with more mature healthcare peers, which means future revenue growth, margin trends, and the pace of adoption of its neurovascular and thrombectomy technologies will be important in determining whether the stock's valuation range holds.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.